In brief
In a significant move, the FDA has issued over 100 warning letters to telehealth companies, including Hims, for promoting unofficial versions of popular weight-loss medications like Wegovy and Ozempic. The agency claims these companies mislead consumers by suggesting their products have the same active ingredients as FDA-approved drugs. This action is part of a broader initiative directed by President Trump to ensure truthful pharmaceutical advertising across various media platforms.
For the first time, federal health officials are targeting telehealth companies, including popular firms like Hims, that are promoting unofficial versions of prescription drugs. This initiative is part of a broader crackdown on misleading pharmaceutical advertising, as highlighted in a recent statement from the FDA.
The FDA has issued warning letters to over 100 online prescribing companies, advising them to cease using 'false and misleading' promotional wording. This includes claims suggesting that these companies' products contain the same active ingredients as FDA-approved medications.
Among those cited was Hims, a company that has gained immense traction selling lower-cost versions of blockbuster weight-loss injections. The FDA claims that Hims' advertisements mislead consumers regarding the equivalence of their products to authorized FDA options like Wegovy and Ozempic, emphasizing that their formulations are produced by specialty pharmacies and lack FDA review.
President Trump’s recent memo directed Health Secretary Robert F. Kennedy Jr. and the FDA to ensure that pharmaceutical advertisements remain truthful and non-deceptive. This marks a shift in the FDA's response strategy, which previously relied on more bureaucratic approaches.
Following scrutiny from Washington, the FDA's recent letters included demands to halt misleading practices, reflecting a growing concern over telehealth marketing tactics, particularly regarding advertisements that do not disclose medication risks.
Hims and other companies have capitalized on the demand for weight-loss medications by selling customized dosages and formulations, but controversy persists over the legitimacy of their claims.
